Altimmune Announces Patient Enrollment Begins In PERFORMA Phase 3 Trial Of Pemvidutide In MASH, Enrolling About 1,790 Patients Across Two Cohorts, 52-Week Data Expected In 2029

뉴스 본문을 불러오고 있어요.

Altimmune Announces Patient Enrollment Begins In PERFORMA Phase 3 Trial Of Pemvidutide In MASH, Enrolling About 1,790 Patients Across Two Cohorts, 52-Week Data Expected In 2029 | 웨이프 WAPE

Altimmune Announces Patient Enrollment Begins In PERFORMA Phase 3 Trial Of Pemvidutide In MASH, Enrolling About 1,790 Patients Across Two Cohorts, 52-Week Data Expected In 2029

기사 요약

관련 종목

댓글 —